This week in therapeutics

Indication

Target/marker/pathway

Summary

Licensing status

Publication and contact information

Cardiovascular disease

Ischemia/reperfusion injury

Protein tyrosine phosphatase non-receptor type 5 (PTPN5; STEP); p38 mitogen-activated protein kinase
(p38 MAPK; MAPK14)

Rat studies identified a degradation-resistant STEP peptide that could help treat ischemia/reperfusion injury. In rats, transient ischemia activated p38 MAPK and initially increased levels of the p38 inhibitor STEP compared with no ischemia, although STEP was eventually degraded. In the rat model, i.v. injection of a cell-permeable, degradation-resistant TAT-STEP-c-Myc (MYC) peptide decreased both p38 MAPK activation and brain damage compared with vehicle injection. Next steps include testing the effects of the peptide on long-term recovery and in stroke models with significant comorbidities.

SciBX 6(47); doi:10.1038/scibx.2013.1350
Published online Dec. 12, 2013

Patent application filed; licensed by Tyrosine Pharma

Deb, I. et al. J. Neurosci.; published online Nov. 6, 2013;
doi:10.1523/JNEUROSCI.2346-12.2013
Contact: Surojit Paul, University of New Mexico, Albuquerque, N.M.
e-mail:
spaul@salud.unm.edu